Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
RegulatoryapprovedAtebriozPositive
AI Analysis
Summary
Mirum Pharmaceuticals and Incyte announced U.S. FDA approval of Atebrioz (zilurgisertib) for treating Fibrodysplasia Ossificans Progressiva in adult and pediatric patients. This represents a regulatory milestone for a therapy targeting a rare genetic disorder.
Outcome Details
U.S. FDA approval for adult and pediatric patients with Fibrodysplasia Ossificans Progressiva
Importance:9/10
Sentiment:
0.90
FDA approvalrare diseasepartnership
Related Companies
Read the original article
Published by yahoo_finance on September 25, 2026 11:00 PM